Open Access Full Text Article

REVIEW

Progress in the identification of gene mutations involved in multiple myeloma

Ying Hu[1]
Wenming Chen[2]
Jingbo Wang[1]

[1]Department of Hematology, Aerospace Central Hospital of Peking University, Beijing, People's Republic of China; [2]Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China

Abstract: Sequencing studies have been used to determine a spectrum of multiple myeloma (MM) mutations. Mutation of certain genes, including *KRAS, NRAS, TP53, FAM46C, DIS3* and *BRAF*, have a high recurrence rate and may play important roles in the pathogenesis, progression and prognosis of MM. Mutations in *DIS3*, which encodes a highly conserved RNA exonuclease, lead to loss of function. The expression of *FAM46C* is highly correlated with the expression of ribosomal protein, but the exact function of *FAM46C* mutation is unclear. There are mutants of *IRF4*, which is considered an MM survival factor. Mutations in the gene coding for the DNA damage-binding protein (*DDB1*) may affect interactions with *CUL4A*, which is part of the cereblon (*CRBN*) ubiquitin ligase complex. *IRF4* is part of the complex, which binds to DNA. These findings might explain the resistance to immunomodulatory. *TP53* deletion or mutation is often present in B-cell malignancies and is associated with low response rates. Myeloma pathogenic mutations in *ATM* have been found in adult lymphatic tumors. *XBP1* and *PSMB5* mutations may be related to bortezomib resistance. Multiple gene mutations (*KRAS, NRAS* and *BRAF*) involved in the same pathway were found a single patient. Identification of driver gene mutations has brought great hope to the field of individualized, targeted medicine for MM.

Keywords: multiple myeloma, cytogenetic abnormalities, gene mutations

Cytogenetic risk stratification has been established in multiple myelo ma (MM). However, cytogenetic abnormalities are not sufficient to fully explain the occurrence, progression and prognosis of MM. The study of gene mutations involved in MM has taken a leap forward with the recent publication of two sequencing studies of 270 cases that represent a spectrum of MM mutation.[1] Mutations with a high recurrence rate, such as those seen in *KRAS, NRAS, TP53, FAM46C, DIS3* and *BRAF*, may play important roles in the pathogenesis, progression and prognosis of MM. The identification of the roles of *CRBN, IKZF1* and *IKZF3* in treatment with immune modulators, and *XBP1*s and *IRE1* in treatment with proteasome inhibitors, as well as drug targets such as *BRAF*, have evolved our understanding of diseases such as MM and emphasize the necessity of individualized treatment. The presence of clone heterogeneity at baseline, linear and branching clonal evolution, and therapeutic selection of resistant mutations point to an urgent need for cloning strategies to quickly, accurately and comprehensively assess the patient's genetic mutation profile to guide accurate treatment. Second-generation sequencing has been instrumental in understanding the genetic spectrum and complexity of subclones. Individual gene mutation profiling before treatment and clonal evolution during treatment will form the basis of individualized treatment and

Correspondence: Wenming Chen
Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China
Email 13910107759@163.com

comprise the standard of future treatment. The integration of MM cytogenetics and gene mutations can be used to improve MM classification, track clonal changes, generate a more accurate prognosis and guide treatment more effectively.[2]

Cytogenetic abnormalities associated with MM

MM is a hematologic malignancy marked by strong heterogeneity throughout the clinical course. Survival ranges from less than 1 year of invasive disease to more than 10 years of inert disease. Therefore, prognostic factors and risk stratification assessment are very important for determining treatment strategies and predicting survival. Cytogenetics and fluorescence in situ hybridization (FISH) have been recognized as important players in risk stratification, especially in the identification of high-risk MM. Nearly half of all monoclonal gammopathy of undetermined significance (MGUS) and MM tumors are hyperdiploid (HRD). Strikingly, HRD tumors rarely have a primary immunoglobulin (Ig)H translocation, whereas non-HRD tumors usually do. Although it has been proposed that non-HRD and HRD tumors represent different pathways of pathogenesis, the timing, mechanism and molecular consequences of hyperdiploidy are unknown. In any case, patients with HRD tumors seem to have a better prognosis than those with non-NHRD tumors. The detection of t(4,14), t(14,16), and del(17p) by FISH is considered high-risk;[3] t(11;14) and t(6;14) confer a good prognosis, while t(14,20) is rare and associated with a poor prognosis. Chromosome 1 abnormalities are common in MM, usually in progressive MM, and are associated with resistance to chemotherapy. Lai et al found that 1q21 amplification and del(p53) were related to disease progression after initial treatment, lgH rearrangement and chromosome 1 abnormality were related to the shortening of progression-free survival (PFS), and the survival period for patients with MM with t(14,16) was shorter after conventional chemotherapy.[4]

Treatment based on cytogenetic risk stratification has yielded clinical benefits, and new targeted drugs have improved outcomes in patients with high-risk cytogenetic abnormalities. Bortezomib (BTZ) can partially overcome the adverse prognosis associated with t(4,14) and del(17p), but is not effective for t(4,14) combined with del(17p).[5] High-dose chemotherapy followed by maintenance with a new drug (BTZ or lenalidomide) can improve the poor

prognosis associated with high-risk cytogenetic abnormalities, and the 5-year survival rate is similar to that of the standard-risk patients.[6] Maintenance therapy with lenalidomide following autologous hematopoietic stem cell transplantation is considered to be the recommended regimen for patients at risk, especially those who did not achieve a very good partial response or above. Maintenance therapy with BTZ is recommended for patients with moderate or high risk.[7]

High-frequency gene mutations in MM

A powerful approach to understanding the molecular basis of cancer is whole-genome sequencing or exon sequencing, which compare the sequencing results of an individual's tumor cells with their normal cells to identify acquired somatic mutations. *DIS3* encodes the highly conserved RNA exonuclease, which is the catalytic part of the exosome complex, involved in regulating the processing and abundance of all RNA. The multiple *DIS3* mutations identified thus far lead to loss of function, which suggests that abnormal regulatory protein translation via *DIS3* mutation could be a canceration mechanism of MM.[8] Further evidence for translational control in the pathogenesis of MM comes from the mutation of *FAM46C*. The expression of *FAM46C* is highly correlated with the expression of ribosomal proteins; however, its exact function remains unclear.[9] The *BRAF* mutation has important clinical significance because such patients can benefit from *BRAF* inhibitors, which have shown great clinical activity in some studies and may have an effect on MM.[10] *PRDM1* encodes a transcriptional inhibitor involved in plasma cell differentiation and acts as a tumor suppressor gene in diffuse large B-cell lymphoma (DLBCL). Mutations affecting its function have been described in DLBCL, but the role of *PRDM1* in MM is unknown. *PRDM1* was found to have recurrent missense or truncated shift mutations, or splicing site mutations.[11] Knockout of *EGR1* in MM cells can remove JUN-induced MM growth inhibition and apoptosis, and has been reported to be a mechanism of drug resistance in myeloma cells.[12] *IRF4* is considered an MM survival factor, and RNA interference screening showed that inhibition of IRF4 transcripts resulted in the unviability of MM cell lines. A missense mutation of *IRF4* has been identified, for which K123R is the repeated hot spot.[13] *SP140* is a lymphoid-restricted homologue of *SP100* that is expressed in plasma cells.

Studies have confirmed that *SP140* is a sensitive site for chronic lymphocytic leukemia, mediated by a decrease in the level of *SP140* mRNA.[14] Two truncation mutations and one nonsense mutation of *SP140* have been observed in MM, but the clinical effects are unclear. *XBP1* mutations that have been identified in association with proteasome resistance may alter sensitivity to proteasome inhibitors; however, these effects are speculative.[15] *CYLD* mutations, have been observed in MM through deletion and mutation inactivation.[16] Recently, *PTPRD*, which dephosphorylates STAT3 and increases IL-6 levels, has been investigated as a tumor suppressor gene in MM.[17] Mutations in the gene coding for the DNA damage-binding protein (*DDB1*) may affect interactions with *CUL4A*, which is part of the cereblon (*CRBN*) ubiquitin ligase complex. *IRF4* is part of the complex, which binds to DNA. These findings might explain the resistance to immunomodulatory and steroid drugs, respectively.[7] *CCND1* point mutation was found, and *FGFR3* was initially considered to be a key driver of t(4,14) myeloma.[18] Cereblon is a key therapeutic target for immunomodulators. Single nucleotide polymorphisms (SNPs) of *CRBN* were found in newly diagnosed refractory/relapse patients, but no *CRBN* mutations were found in those who were resistant to lenalidomide. SNP$_S$ were also found in *DDB1*, but only one patient had a heterozygous mutation. These findings suggest that *CRBN* and *DDB1* mutations are rare and may have limited effects on *CRBN-associated drug* resistance.[19] Sequencing of a multidrug-resistant, extramedullary recurrent tissue revealed frame-shift and point mutations in *CRBN*, as well as a point mutation in *PSMG2* and a point mutation of *NR3C1*. These mutations may be associated with drug resistance.[20] *TP53* deletion or mutation is often present in B-cell malignancies and is associated with low response rates. Analyses of the p53 pathway and upstream signaling molecules have included *MYC, RAS, ARF, MDM2, ATM* and *TP53*. Deletion and mutation of *ATM* or *TP53* are commonly seen in DLBCLs and mantle cell lymphomas, whereas *RAS* mutations only occur in MM and plasma cell leukemia (PCL).[21] *ATM* mutations have been found in some adult lymphatic tumors. To study the incidence of *ATM* mutations in MM, 45 *ATM* mutations were screened, 2 of which were myeloma pathogenic.[22] Downregulation of *XBP1*, which is highly expressed in malignant plasma cells, is associated with proteasome inhibitor resistance. Certain point mutations of *XBP1* may be associated with the transcriptional activity of *XBP1*, and some studies have

shown that low *XBP1* protein levels can predict poor efficacy of bortezomib (BTZ). Studies have shown that BTZ-induced *PSMB5* mutations lead to resistance to different proteasome inhibitors. However, *PSMB5* mutations have not been confirmed in clinical specimens that are resistant to BTZ.[23]

Characteristics and clinical significance of MM gene mutation

Targeted sequencing analysis revealed that *KRAS* was the most common mutated gene (36%), followed by *NRAS* (20%), *TP53* (16%), *DIS3* (16%) and *FAM46C* (12%). Initial treatment for MM is usually the induction of high-quality remission, including complete response. However, there is recurrence in almost all patients, which is best explained by the presence of tumor clonal heterogeneity at the time of diagnosis, with differential sensitivity to different drugs leading to clonal selection and evolution. Successful treatment requires the targeting of a wide range of targets including tiny subclones. Therefore, it is necessary to monitor the gene changes of the tumor cell population under the pressure of treatment selection to evaluate the efficacy.[15]

Mutation diversity affects different nodes of the signal network and is an inherent feature of myeloma.[24] Multiple gene mutations (*KRAS, NRAS and BRAF*) have been found in the same patient, with mutation of different genes located in the same pathway. Studies have found that *FAM46C* and *DIS3* are likely to be the driver genes of MM.[18] Other studies have found that *BRAF, TRAF3, CYLD* and *RB1* are involved in the pathogenesis of MM.[25] The identification of such driver gene mutations in MM has brought great hope to the field of individualized medicine. Patients with a unique set of mutations can now receive appropriate targeted therapy.

Some mutations are early molecular events, while others occur as the tumor progresses. Another complication is the coexistence of one or more mutations in *KRAS, NRAS* or *BRAF* in one master clone (ie, in all tumor cells).[26] In a study of a group of refractory MM patients with multidrug resistance who were previously treated with a proteasome inhibitor/immunomodulator or both, the mutation rate of the RAS pathway (*KRAS, NRAS, BRAF*) was increased by 72% compared with newly diagnosed MM; the mutation rates of *TP53* and *CRBN* were 26% and 12%, respectively.[27] Genetic mutations were also detected in patients with recurrent MM who participated in a clinical trial of BTZ. Mutations in

NRAS were associated with a low response rate and rapid progression after a single-drug regimen of BTZ. *KRAS* mutation did not decrease the sensitivity to BTZ.[28]

Non-myeloma plasma cell disease mutations are significantly lower in patients with myeloma. The spectrum of mutations from MGUS and amyloidosis to MM represents a complex pattern of changes.[29] The gene mutation rates among refractory/recurrent patients and newly diagnosed patients are 27.2% and 6.6%, respectively,[30] while the rates in MM, primary PCL and secondary PCL are 59.8%, 41.7% and 63.6%, respectively.[31] Among the newly diagnosed high-risk del(17p) MM patients, *TP53* is the most common (27.8%) mutated gene.[7] *NRAS* and *KRAS* mutations are less common in high-risk patients, including those with a del (17p) mutation, and more common in relapsed patients.[32] In fact, *TP53* mutations are more common in unselected MM patients than del(17p) patients. In the non-del(17p) group in one report, *TP53* mutations were associated with shortened event-free survival and overall survival (OS).[26] The most common mutations in patients with 1q21 included *TP53* (38%) and *KRAS* (25%).[33] One study showed that patients with mutations in the *RAS* pathway (NF-KB) had a neutral prognosis, while *CCND1* and DNA repair pathway mutations (*TP53, ATM, ATR* and *ZNFHX4*) were associated with a poor prognosis. Mutations in *IRF4* and *EGR1* were related to good OS. The recurrence of adverse prognostic mutation factors and International Staging System scoring were used to generate an international staging mutation score to identify high-risk patients with recurrence and early death[34] (Figure 1). A study was undertaken to compare the prognosis of patients receiving autologous hematopoietic stem cell transplantation induced by immunomodulators and/or proteasome inhibitors with or without *TP53* mutations. Before transplantation, 62% of both groups (*p*=0.97) achieved part response above efficacy; the recurrence rates of the two groups after transplantation were 68% and 42%, respectively (*p*=0.01). The median PFS rates were 8 months and 28 months (*P*<0.001), and the median OS rates were 21 months and 56 months (*P*<0.001), in the patients with and without *TP53* mutations, respectively. Hence, *TP53* mutation is an independent prognostic factor for the progression of autologous transplantation.[35]

Persistent response to *BRAF* inhibitors in MM patients with a single *BRAF* mutation has been recently reported. It has been shown that BRAF inhibitors can be used to successfully treat recurrent/refractory myeloma with *BRAF* mutation. MDM2 inhibitors target *TP53* deletion or mutation, block the interaction between MDM22-p53 proteins and play an anti-myeloma role. Inhibition of MAPK kinase (MEK) can be used for the treatment of *KRAS/NRAS* mutant clones. *FGFR3* antibodies and MMSET inhibitors are being evaluated. *KRAS* and *ATM* mutations affect the downstream signals of MEK and can be used as therapeutic targets. The PI3K pathway plays a role in regulating downstream pathways such as AKT and MTOR, and a large number of clinical trials are studying PIK3 inhibitors[20] (Table 1).

The emergence of drug-resistant subclones is one of the root causes of MM recurrence. Whole-genome sequencing at the time of onset and recurrence in 56 MM patients showed that those with complete remission relapsed

Figure 1 Recurrent gene mutation incidence in the newly diagnosed MM.[15,26,34]

Table 1 Clinical significance of mutant genes

	Mutant genes
Likely associated with pathogenesis	*DIS3, FAM46C, BRAF, TRAF3, CYLD, RB1*
Likely associated with drug resistance	*XBP1, CRBN, PSMG2, NR3C1*
Likely associated with outcome	*TP53, ATM, KRAS, NRAS, EGR1, IRF4*
Drug inhibitors	*BRAF* inhibitors, MDM2 inhibitors target *TP53*, MEK inhibitors target *RAS*

mainly through the form of branching evolution, which was characterized by the addition of new mutations and changes in the mutant spectrum. Patients with partial remission had similar mutant profiles at onset and recurrence. There was no significant difference in the gene mutation profile at the time of recurrence between the patients observed and those who received lenalidomide for maintenance.[36] Analysis of the 60 driver mutations that were identified was used to determine the corresponding pathways for use as therapeutic targets. Drugs that target survival pathways, such as venetoclax, a BCL2 inhibitor, have been shown to be effective in treating myeloma.[37]

Conclusion

The spectrum of mutants identified in recent studies is insufficient to define their role and place in the individualized treatment of MM. It is not yet clear whether drugs that target these mutational changes will produce a meaningful or lasting response in patients.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Lohr JG, Stojanov P, Carter SL. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. *Cancer Cell*. 2014;25(1):91–101. doi:10.1016/j.ccr.2013.12.015
2. Kortüm KM, Langer C, Monge J. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M 3 P) in −17p high risk disease. *Br J Haematol*. 2015;168(4):507–510. doi:10.1111/bjh.13171
3. Munshi NC, Anderson KC, Bergsagel PL. Consensus recommendations for risk stratification in multiple myeloma: report of the International myeloma workshop consensus panel 2. *Blood*. 2011;117 (18):4696–4700. doi:10.1182/blood-2010-10-300970
4. Lai YY, Huang XJ, Cai Z. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China. *Chin Med J*. 2012;125(15):2663–2670.
5. Sonneveld P, Avet-Loiseau H, Lonial S. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International myeloma working group. *Blood*. 2016;127(24):2955–2962. doi:10.1182/blood-2016-01-631200
6. Kaufman GP, Gertz MA, Dispenzieri A. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. *Leukemia*. 2016;30(3):633–639. doi:10.1038/leu.2015.287
7. Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. *Am J Hematol*. 2016;91 (7):719–734. doi:10.1002/ajh.24402
8. Dziembowski A, Lorentzen E, Conti E, Séraphin B. A single subunit, Dis3, is essentially responsible for yeast exosome coreactivity. *Nat Struct Mol Biol*. 2007;14(1):15–22. doi:10.1038/nsmb1184
9. Tanay A, Regev A, Shamir R. Conservation and evolvability in regulatory networks: the evolution of ribosomal regulation in yeast. *Proc Natl Acad Sci U S A*. 2005;102(20):7203–7208. doi:10.1073/pnas.0502521102
10. Kim K, Kong S-Y, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. *Br J Haematol*. 2010;149(4):537–549. doi:10.1111/bjh.2010.149.issue-4
11. Lin FR, Kuo HK, Ying HY. Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. *Cancer Res*. 2007;67(24):11914–11923. doi:10.1158/0008-5472.CAN-07-1868
12. Chen L, Wang S, Zhou Y. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. *Blood*. 2010;115(1):61–70. doi:10.1182/blood-2009-12-255992
13. Shaffer AL, Emre NC, Lamy L. IRF4 addiction in multiple myeloma. *Nature*. 2008;454(7201):226–231. doi:10.1038/nature07064
14. Di Bernardo MC, Crowther-Swanepoel D, Broderick P. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. *Nat Genet*. 2008;40(10):1204–1210. doi:10.1038/ng.126
15. Kortüm KM, Langer C, Monge J. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M 3 P). *Ann Hematol*. 2015;94(7):1205–1211. doi:10.1007/s00277-015-2344-9
16. Demchenko YN, Glebov OK, Zingone A. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. *Blood*. 2010;115(17):3541–3552. doi:10.1182/blood-2009-12-255992
17. Kamada Y, Sakata-Yanagimoto M, Sanada M. Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis. *Int J Hematol*. 2012;96(4):492–500. doi:10.1007/s12185-012-1171-1
18. Chapman MA, Lawrence MS. Initial genome sequencing and analysis of multiple myeloma. *Nature*. 2011;471(7339):467–472. doi:10.1038/nature09833
19. Thakurta A, Gandhi AK, Waldman MF. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. *Leukemia*. 2014;28 (5):1129–1131. doi:10.1038/leu.2013.315
20. Egan JB, Kortuem KM, Kurdoglu A. Extramedullary myeloma whole genome sequencing reveals novel mutations in cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. *Br J Haematol*. 2013;161(5):748–751. doi:10.1111/bjh.12291
21. Tessoulin B, Eveillard M, Lok A. p53 dysregulation in B-cell malignancies: more than a single gene in the pathway to hell. *Blood Rev*. 2017;31(4):251–259. doi:10.1016/j.blre.2017.03.001
22. Austen B, Barone G, Reiman A. Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients. *Br J Haematol*. 2008;142(6):925–933. doi:10.1111/j.1365-2141.2008.07281.x

23. Verbrugge SE, Assaraf YG, Dijkmans BA. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoidarthritis. *J Pharmacol Exp Ther*. 2012;341(1):174–182.

24. Leich E, Weißbach S, Klein HU. Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules. *Blood Cancer J*. 2013;3:e102. doi:10.1038/bcj.2012.47

25. Keats JJ, Fonseca R, Chesi M. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell*. 2007;12(2):131–144. doi:10.1016/j.ccr.2007.07.003

26. Bolli N, Avet-Loiseau H, Wedge DC. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nat Commun*. 2014;5:2997. doi:10.1038/ncomms5972

27. Kortüm KM, Mai EK, Hanafiah NH. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. *Blood*. 2016;128(9):1226–1233. doi:10.1182/blood-2016-02-698092

28. Mulligan G, Lichter DI, Di Bacco A. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. *Blood*. 2014;123(5):632–639. doi:10.1182/blood-2013-05-504340

29. Rossi A, Voigtlaender M, Janjetovic S. Mutational landscape reflects the biological continuum of plasma cell dyscrasias. *Blood Cancer J*. 2017;7(2):e537. doi:10.1038/bcj.2017.19

30. Mithraprabhu S, Khong T, Ramachandran M. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. *Leukemia*. 2017;31 (8):1695–1705. doi:10.1038/leu.2016.366

31. Lionetti M, Barbieri M, Todoerti K. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. *Oncotarget*. 2015;6 (27):24205–24217. doi:10.18632/oncotarget.4434

32. Chng WJ, Gonzalez-Paz N, Price-Troska T. Clinical and biological significance of RAS mutations in multiple myeloma. *Leukemia*. 2008;22(12):2280–2284. doi:10.1038/sj.leu.2404889

33. Shah GL, Landau H, Londono D. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. *Leuk Lymphoma*. 2017;58(8):1823–1831. doi:10.1080/10428194.2016.12 60126

34. Walker BA, Boyle EM, Wardell CP. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. *J Clin Oncol*. 2015;33 (33):3911–3920. doi:10.1200/JCO.2014.59.1503

35. Gaballa S, Saliba RM, Srour S. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. *Am J Hematol*. 2016;91(10):E442–E447. doi:10.1002/ ajh.24487

36. Jones JR, Weinhold N, Ashby C. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. *Haematologica*. 2019. doi:10.3324/ haematol.2018.202200

37. Morgan GJ, Rasche L. Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic. *Expert Rev Hematol*. 2018;11(7):513–523. doi:10.1080/ 17474086.2018.1489718